Keratoconus treatment and cause
March 14 2017 by Ray Sahelian, M.D. natural health web site

keratoconus is a rare eye disorder most often appearing in one's teens or early twenties, keratoconus is a progressive disease in which the normally round cornea thins and begins to bulge into a cone-like shape. This cone shape deflects light as it enters the eye on its way to the light-sensitive retina, causing distorted vision. This visual condition can occur in one or both eyes.

Keratoconus treatment

When keratoconus has not advanced, eyeglasses are often helpful in correcting nearsightedness (myopia) and astigmatism; however, as the disease progresses, the cornea becomes too distorted to benefit from eyeglasses alone. Eventually, rigid contact lenses are prescribed to aid in reshaping the corneal surface to provide optimal visual correction.
     Surgical options also are available for those patients who can no longer benefit from contact lenses. Intacts are small C-shaped silicone rings that are placed into the cornea to reduce the amount of astigmatism. In some cases, the patient may no longer need contact lenses, or if the patient has been unable to wear contact lenses, he or she may find that wearing lenses is possible again.


Keratoconus as the most common cause of ectasia is one of the leading cause of corneal transplants worldwide. There is a strong associations between KC and several immune conditions of autoimmune diseases and allergic immune disorders which may point to the role of the immune system in the pathogenesis of KC. Cornea. 2010. The Association of Keratoconus With Immune Disorders.


Eye (London). 2015. Keratoconus: an inflammatory disorder? Keratoconus has been classically defined as a progressive, non-inflammatory condition, which produces a thinning and steepening of the cornea. Its pathophysiological mechanisms have been investigated for a long time. Both genetic and environmental factors have been associated with the disease. Recent studies have shown a significant role of proteolytic enzymes, cytokines, and free radicals; therefore, although keratoconus does not meet all the classic criteria for an inflammatory disease, the lack of inflammation has been questioned. The majority of studies in the tears of patients with keratoconus have found increased levels of interleukin-6 (IL-6), tumor necrosis factor-α(TNF-α), and matrix metalloproteinase (MMP)-9. Eye rubbing, a proven risk factor for keratoconus, has been also shown recently to increase the tear levels of MMP-13, IL-6, and TNF-α. In the tear fluid of patients with ocular rosacea, IL-1α and MMP-9 have been reported to be significantly elevated, and cases of inferior corneal thinning, resembling keratoconus, have been reported.


Clin Ophthalmol. 2013. Keratoconus: current perspectives. Keratoconus is characterized by progressive corneal protrusion and thinning, leading to irregular astigmatism and impairment in visual function. The etiology and pathogenesis of the condition are not fully understood. However, significant strides have been made in early clinical detection of the disease, as well as towards providing optimal optical and surgical correction for improving the quality of vision in affected patients. The past two decades, in particular, have seen exciting new developments promising to alter the natural history of keratoconus in a favorable way for the first time. This comprehensive review focuses on analyzing the role of advanced imaging techniques in the diagnosis and treatment of keratoconus and evaluating the evidence supporting or refuting the efficacy of therapeutic advances for keratoconus, such as newer contact lens designs, collagen crosslinking, deep anterior lamellar keratoplasty, intracorneal ring segments, photorefractive keratectomy, and phakic intraocular lenses.


Keratoconus studies and research
The possible relationship between keratoconus and magnesium deficiency.
Ophthalmic Physiol Opt. 2005. Instituto de la Vision, Mar del Plata, Argentina.
The cause of keratoconus is unknown. However, an earlier report demonstrated magnesium deficiency in keratoconus patients, and suggested that magnesium deficiency could pathologically affect the mechanisms of the cornea. Experimental and clinical papers concerning a possible relationship between keratoconus and magnesium deficiency were reviewed. These studies have demonstrated molecular and cellular alterations specific to the keratoconic cornea, including: thinning and fragmentation of membranes, degenerated cells and collagen fibres, swelling of the mitochondria, and biochemical abnormalities in protein synthesis. Similar alterations have reportedly been induced by magnesium deficiency. This review suggests a possible relationship between the specific keratoconic disorders and the alteration induced by magnesium deficiency at the intracellular and extracellular levels. Although the etiology of keratoconus is still unknown, this paper may give some new ideas for further experimental and clinical studies on the etiology of keratoconus.


Rev Med Suisse. 2014. Keratoconus treatment by corneal cross-linking (CLX)]. Keratoconus is a disease of the cornea that usually begins during puberty and progressively weakens its biomechanical structure. Keratoconic eyes show a conic shape and progressive thinning, both leading to irregular astigmatism and reduced vision that cannot be corrected by glasses. In early cases, special contact lens can partly compensate for the visual loss while they do not stop disease progression. Until recently, the only treatment option was a corneal transplant. In 1999, a technique called corneal collagen cross-linking (CXL) was used in human corneas suffering from keratoconus for the first time. CXL uses a process called photopolymerization to halt the progression of keratoconus with an efficacy of more than 95%. Today our challenge is to screen and identify patients early enough to offer a treatment on time before irreversible vision loss develops.


Keratoconus - Eyesight Rx testimonials
I was diagnosed in 1996 with keratoconus (bilateral). I had a corneal transplant in my left eye in 1998. My vision improved to 20/60 with corrective lenses. However it was very difficult and at times impossible to read small, medium, and at times large print. Driving at night was out of the question for me. After taking eyesight Rx I am able to read and respond to my email with less strain than before; as I can now see the monitor and the letters on the key board much clearer. Colors are brighter and lively. I can honestly say my vision has improved and so has my life as a result of taking Eyesight Rx. I noticed the results within the first few hours after melting half a tablet of Eyesight Rx under my tongue. I now use Eyesight Rx about 4 or 5 days a week and it helps me see clearer. Female, age 26, Bakersfield, CA.


Q. i have keratoconus disease, i want to know whether your eyes product is efficient for my disease and can help me to cure it enormously. I am from India.
   A. We only have one case report so we don't know if Eyesight Rx will help other people with this condition.


Q. i am patient with keratoconus, will taking of Eyesight Rx help me in improving my vision?
   A. We have had feedback from one person that with keratoconus who tried Eyesight Rx. We have not done any formal studies with Eyesight Rx and keratoconus so we don't know. If your doctor approves you can try a third or half a tablet four or 4 times a week. If you do try it, please give us feedback.


Q.  I have had keratoconus for the past 10 years and have to depend on RGP lenses to see well. Fortunatly I am now 34 years old and my eyes have seemed to stabalise. I can wear my lenses for 12 hours or more each day and find them reasonably confortable. I have researched this complaint for the past few years and I think that the problem stems from a deficiency in some kind of nutrient or an allergy to some kind of food. Have you had any experience with keratoconus disorder and would you recommend any supplements that may help me see a improvement.
   A. I don't have any clinical experience with keratoconus at this time.